Aurobindo Pharma Limited (AUROPHARMA) - Total Liabilities
Based on the latest financial reports, Aurobindo Pharma Limited (AUROPHARMA) has total liabilities worth Rs206.19 Billion INR (≈ $2.23 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore AUROPHARMA long-term investments to assets to see how much of total assets are deployed in long-term investments.
Aurobindo Pharma Limited - Total Liabilities Trend (2004–2026)
This chart illustrates how Aurobindo Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aurobindo Pharma Limited asset portfolio.
Aurobindo Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Aurobindo Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Max Healthcare Institute Limited
NSE:MAXHEALTH
|
India | Rs64.84 Billion |
|
Shenzhen Envicool Technology Co Ltd
SHE:002837
|
China | CN¥4.28 Billion |
|
Stifel Financial Corporation
NYSE:SF
|
USA | $38.89 Billion |
|
Guangxi Guiguan Electric Power Co Ltd
SHG:600236
|
China | CN¥30.19 Billion |
|
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
|
USA | $4.22 Billion |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
China | CN¥16.19 Billion |
|
SailPoint, Inc. Common Stock
NASDAQ:SAIL
|
USA | $683.73 Million |
|
SARTORIUS (UNSP.ADS)/1/5
F:SRT0
|
Germany | €5.98 Billion |
Liability Composition Analysis (2004–2026)
This chart breaks down Aurobindo Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AUROPHARMA equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aurobindo Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aurobindo Pharma Limited (2004–2026)
The table below shows the annual total liabilities of Aurobindo Pharma Limited from 2004 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs206.19 Billion ≈ $2.23 Billion |
+20.31% |
| 2025-03-31 | Rs171.38 Billion ≈ $1.85 Billion |
+12.60% |
| 2024-03-31 | Rs152.21 Billion ≈ $1.65 Billion |
+16.74% |
| 2023-03-31 | Rs130.38 Billion ≈ $1.41 Billion |
+39.48% |
| 2022-03-31 | Rs93.48 Billion ≈ $1.01 Billion |
-21.61% |
| 2021-03-31 | Rs119.25 Billion ≈ $1.29 Billion |
-1.47% |
| 2020-03-31 | Rs121.03 Billion ≈ $1.31 Billion |
-3.65% |
| 2019-03-31 | Rs125.62 Billion ≈ $1.36 Billion |
+33.37% |
| 2018-03-31 | Rs94.19 Billion ≈ $1.02 Billion |
+36.99% |
| 2017-03-31 | Rs68.75 Billion ≈ $743.55 Million |
-24.47% |
| 2016-03-31 | Rs91.02 Billion ≈ $984.40 Million |
+17.71% |
| 2015-03-31 | Rs77.33 Billion ≈ $836.27 Million |
+35.33% |
| 2014-03-31 | Rs57.14 Billion ≈ $617.95 Million |
+22.72% |
| 2013-03-31 | Rs46.56 Billion ≈ $503.54 Million |
+19.76% |
| 2012-03-31 | Rs38.88 Billion ≈ $420.45 Million |
+13.57% |
| 2011-03-31 | Rs34.23 Billion ≈ $370.22 Million |
+15.73% |
| 2010-03-31 | Rs29.58 Billion ≈ $319.89 Million |
-0.81% |
| 2009-03-31 | Rs29.82 Billion ≈ $322.50 Million |
+18.94% |
| 2008-03-31 | Rs25.07 Billion ≈ $271.15 Million |
-4.19% |
| 2007-03-31 | Rs26.17 Billion ≈ $283.01 Million |
+39.78% |
| 2006-03-31 | Rs18.72 Billion ≈ $202.47 Million |
+32.28% |
| 2005-03-31 | Rs14.15 Billion ≈ $153.06 Million |
+24.05% |
| 2004-03-31 | Rs11.41 Billion ≈ $123.39 Million |
-- |
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingred… Read more